# Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years

> **NCT00161785** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 340 (—)

## Conditions studied

- Tick-borne Encephalitis

## Interventions

- **BIOLOGICAL:** FSME-IMMUN 0.5ml

## Key facts

- **NCT ID:** NCT00161785
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** —
- **Final completion:** 2005-07
- **Target enrollment:** 340 (—)
- **Last updated:** 2015-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00161785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00161785, "Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00161785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*